PARP-1 transcriptional activity is regulated by sumoylation upon heat shock
Heat shock and other environmental stresses rapidly induce transcriptional responses subject to regulation by a variety of post‐translational modifications. Among these, poly(ADP‐ribosyl)ation and sumoylation have received growing attention. Here we show that the SUMO E3 ligase PIASy interacts with...
Saved in:
Published in | The EMBO journal Vol. 28; no. 22; pp. 3534 - 3548 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
18.11.2009
Nature Publishing Group UK Springer Nature B.V EMBO Press Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Heat shock and other environmental stresses rapidly induce transcriptional responses subject to regulation by a variety of post‐translational modifications. Among these, poly(ADP‐ribosyl)ation and sumoylation have received growing attention. Here we show that the SUMO E3 ligase PIASy interacts with the poly(ADP‐ribose) polymerase PARP‐1, and that PIASy mediates heat shock‐induced poly‐sumoylation of PARP‐1. Furthermore, PIASy, and hence sumoylation, appears indispensable for full activation of the inducible
HSP70.1
gene. Chromatin immunoprecipitation experiments show that PIASy, SUMO and the SUMO‐conjugating enzyme Ubc9 are rapidly recruited to the
HSP70.1
promoter upon heat shock, and that they are subsequently released with kinetics similar to PARP‐1. Finally, we provide evidence that the SUMO‐targeted ubiquitin ligase RNF4 mediates heat‐shock‐inducible ubiquitination of PARP‐1, regulates the stability of PARP‐1, and, like PIASy, is a positive regulator of
HSP70.1
gene activity. These results, thus, point to a novel mechanism for regulating PARP‐1 transcription function, and suggest crosstalk between sumoylation and RNF4‐mediated ubiquitination in regulating gene expression in response to heat shock. |
---|---|
Bibliography: | ark:/67375/WNG-1WXN78RC-7 Supplementary Figure S1Supplementary Figure S2Supplementary Figure S3Supplementary Figure S4Supplementary Figure S5Supplementary Figure S6Supplementary Figure S2B Original scanSupplementary Figure S4B Original scanSupplementary Figure LegendsReview Process File ArticleID:EMBJ2009279 istex:AEE2E65D24F729F5B927696E673C27B12C832D30 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 PMCID: PMC2782092 Present address: Pepscan Therapeutics BV, Lelystad 8219 PK, The Netherlands These authors contributed equally to this work Present address: UMR INRA/CNRS, Université de Bourgogne, Dijon 21 065, France Present address: ZMBH, University Heidelberg, Heidelberg 69120, Germany Present address: Cell Proliferation Group, MRC Clinical Sciences Centre, London W120NN, UK |
ISSN: | 0261-4189 1460-2075 1460-2075 |
DOI: | 10.1038/emboj.2009.279 |